

Publikationen, Patente

ORCID-ID	Original- arbeiten	Übersichts- arbeiten, Fallberichte, Editorials	Buchkapitel	Abstracts, Konferenz- beiträge	h-Index
0000-0002-3740-1903	67	40	5	120	28

Originalarbeiten

1. M. Boesing, F. Bierreth, K. Abig, S. Giezendanner, A.B. Leuppi-Taegtmeyer, G. Lüthi-Corridori, S. Maier, S. Züsli, J.D. Leuppi, **T. Dieterle**. Effects of serial NT-proBNP measurements in patients with acute decompensated heart failure: Results of the POC-HF pilot trial. *Glob Cardiol Sci Pract* 2024; e202431. doi: 10.21542/gcsp.2024.31.
IF: n.a. **Field:** Cardiac&Cardiovascular Systems.
2. S. Witt, J.B. González-Rubino, R. Martín-Valero, M.J. Vinolo-Gil, **T. Dieterle**. Compression wraps—providing solutions for complex lymphatic presentations. *Lymphatics* 2024; 2: 108-118; doi: 10.3390/lymphatics2020009.
IF: n.a. **Field:** Peripheral Vascular Disease.
3. S. Witt, **T. Dieterle**, S. Gordon, N. Campbell, N. Piller. Climate and climatic variations' Impact on lymphoedema: patient perspective. *Lymphatics* 2024; 2: 119-132; doi: 10.3390/lymphatics2020010.
IF: n.a. **Field:** Peripheral Vascular Disease.
4. J.B.G. Rubiño, S. Witt, R. Martín-Valero, M.J. Viñolo-Gil, **T. Dieterle**. Bilateral axillary web syndrome in a patient with primary lymphoedema of upper limbs and non-Hodgkin lymphoma. *Br J Community Nurs* 2024; 29(Sup4): S32-S35. doi: 10.12968/bjcn.2024.29.Sup4.S32.
IF: n.a. **Field:** Medicine (miscellaneous).
5. J.M. Kröpfl, F.G. Beltrami, H.-J. Gruber, A. Schmidt-Trucksäss, **T. Dieterle**, C.M. Spengler. Circulating Gal-3 and sST2 are associated with acute exercise-induced sustained endothelial activation - possible relevance for fibrosis development? *Exp Physiol* 2023; 108: 1259-1267. doi: 10.1113/EP091277.
IF: 2.6 **Field:** Physiology.
6. M. Boesing, C. Gregoriano, A.E. Minder, C. Abshagen, S. Dahl, **T. Dieterle**, F. Eicher, A.B. Taegtmeyer-Leuppi, I. Rageth, D. Miedinger, E. Wirz, J.D. Leuppi. Predictors for unplanned readmissions within 18 days of hospital discharge: a retrospective cohort study. *Praxis (Bern)* 2023; 112: 57-63. doi: 10.1024/1661-8157/a003985.
IF: n.a. **Field:** Medicine, General&Internal.
7. S.T. Huebner, S. Henny, S. Giezendanner, T. Brack, M. Brutsche, P. Chhajed, C. Clarenbach, **T. Dieterle**, A. Egli, M. Frey, I. Heijnen, S. Iranyi, N.A. Sievi, R. Thrunheer, M. Trendelenburg, M. Kohler, A.B. Leuppi-Taegtmeyer, J.D. Leuppi. Prediction of acute COPD exacerbation in the Swiss Multicenter COPD Cohort Study (TOPDOCS) by clinical parameters, medication use, and immunological biomarkers. *Respiration* 2022; 101: 441-454. Doi: 10.1159/000520196.
IF: 3.7 **Field:** Respiratory System.

8. B.A. Gasser, M. Boesing, R. Schoch, S. Brighenti-Zogg, J.M. Kröpfl, E. Thesenvitz, H. Hanssen, J.D. Leuppi, A. Schmidt-Trucksäss, **T. Dieterle**. High-intensity interval training for heart failure with preserved ejection fraction (HIT-HF) – rationale and design of a prospective, randomized, controlled trial. *Front Physiol* 2021; 12: 734111. doi: 10.3389/fphys.2021.734111.
IF: 4.755. Field: Physiology.
9. C. Becker, M. Gamp, P. Schuetz, K. Beck, A. Vincent, S. Hochstrasse, K. Metzger, M. Widmer, E. Thommen, B. Mueller, C.A. Fux, J.D. Leuppi, R. Schaefert, W. Langewitz, M. Trendelenburg, T. Breithardt, J. Eckstein, M. Osthoff, S. Basetti, S. Hunziker, BEDSIDE-OUTSIDE Study Group. Effect of Bedside compared with outside the room patient case presentation on patients' knowledge about their medical care: a randomized, controlled, multicenter trial. *Ann Intern Med* 2021; 174: 1282-1292. doi: 10.7326/M21-0909.
IF: 51.598. Field: Medicine, Research&Experimental.
10. S. Züsli*, F. Bierreth*, M. Boesing*, P. Haas, K. Abig, S. Maier, G. Corridori, J.D. Leuppi, **T. Dieterle**. Point Of Care with serial NT-proBNP measurement in patients with acute decompensated Heart Failure as a therapy-monitoring during hospitalization (POC-HF): Study protocol of a prospective, unblinded, randomized, controlled pilot trial. *Contemp Clin Trials Commun* 2021; 100825. doi: 10.1016/j.conctc.2021.100825 (* equal contribution).
IF: 1.5 (2022) Field: Medicine, Research&Experimental.
11. J.L. Marmy, J.P. Diedrich, C. Cadus, P. Grendelmeier, A. Tschacher, **T. Dieterle**, P.N. Chhajed, J.D. Leuppi. Adherence to GOLD recommendations among Swiss pulmonologists and general practitioners. *COPD* 2021;18: 9-15. doi: 10.1080/15412555.2020.1859469.
IF: 2.069. Field: Respiratory System.
12. **T. Dieterle**, S. Schaefer, I. Meyer, G. Ackermann, K. Ahmed, R. Hullin. Introduction of sacubitril/valsartan in primary care follow-up of heart failure: A prospective observational study (THESEUS). *ESC Heart Fail* 2020; 7: 1626-1634.
IF: 4.411. Field: Cardiac&Cardiovascular Systems.
13. S. Giezendanner, P. Tschudi, J. Leuppi, **T. Dieterle**, A. Zeller. Effect of guideline revisions by the Swiss Society of Hypertension on blood pressure control in hypertensive patients from primary care. *Swiss Med Wkly* 2020; 150: w20279. doi: 10.4414/smw.2020.20279.
IF: 2.193. Field: Medicine, General&Internal.
14. P. Urwyler, M. Boesing, K. Abig, M. Cattaneo, **T. Dieterle**, A. Zeller, H. Bachler, S. Markun, O. Senn, C. Merlo, S. Essig, E. Ullmer, J. Rutishauser, M.M. Schuurmans, J.D. Leuppi. Reduction of corticosteroid use in outpatient treatment of exacerbated COPD - Study protocol for a randomized, double-blind, non-inferiority study, (The RECUT-trial). *Trials* 2019; 20: 727. doi: 10.1186/s13063-019-3856-8.
IF: 1.883. Field: Medicine, Research&Experimental.
15. C. Gregoriano, **T. Dieterle**, A.L.Breitenstein, S. Dürr S, A. Baum A, S. Giezendanner, S. Maier, A. Leuppi-Taegtmeyer, I. Arnet, K.E.Hersberger, J.D. Leuppi. Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial. *Respir Res* 2019; 20: 273. doi: 10.1186/s12931-019-1219-3.
IF: 3.924. Field: Respiratory System.

16. Handschin*, S. Brighenti-Zogg*, J. Mundwiler, S. Giezendanner, C. Gregoriano, B. Martina, P. Tschudi, J.D. Leuppi, A. Zeller, **T. Dieterle**. Cardiovascular risk stratification in primary care patients with arterial hypertension – Results from the Swiss Hypertension Cohort Study (HccH). *Eur J Prev Cardiol* 2019; doi: 10.1177/2047487319856732 (*equal contribution).
IF: 5.864. **Field:** Cardiac&Cardiovascular Systems.
17. J. Wagner, R. Knaier, D. Infanger, K. Arbeev, M. Briel, T. **Dieterle**, H. Hanssen, O. Faude, R. Roth, T. Hinrichs, A. Schmidt-Trucksäss. Functional aging in health and heart failure – the COMplete study. *BMC Cardiovasc Disord* 2019; 19:180. doi: 10.1186/s12872-019-1164-6.
IF: 2.078. **Field:** Cardiac&Cardiovascular Systems.
18. S. Kind*, S. Brighenti-Zogg*, J. Mundwiler, U. Schüpbach, J.D. Leuppi, D. Miedinger, **T. Dieterle**. Metabolic profile and predictors of cardiorespiratory fitness in a Swiss working population. *J Sports Med* 2019; doi.org/10.1155/2019/5317961 (*equal contribution).
IF: n.a. **Field:** Sports Sciences.
19. P. Urwyler, N. Abu Hussein, P.-O. Bridevaux, P.N. Chajed, T. Geiser, P. Grendelmeier, L. Joos Zellweger, M. Kohler, S. Maier, D. Miedinger, M. Tamm, R. Thurnheer, **T. Dieterle**, J.D. Leuppi. Predictive factors for exacerbation and re-exacerbation in chronic pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort. *Multidiscip Respir Med* 2019; 14: 7. doi: 10.1186/s40248-019-0168-5.
IF: 0.838. **Field:** Respiratory System.
20. C. Gregoriano, **T. Dieterle**, A.-L. Breitenstein, S. Dürr, A. Baum, S. Maier, I. Arnet, K.E. Hersberger, J.D. Leuppi. Use and inhalation technique of inhaled medication in patients with asthma and COPD: Data from a randomized controlled trial. *Resp Res* 2018; 19 : 237. doi: 10.1186/s12931-018-0936-3
IF: 3.829. **Field:** Respiratory System.
21. T. Carron, P.O. Bridevaux, K. Lörvall K, R. Parmentier, J.B. Moix, V. Beytrison, R. Pernet. C. Rey, P.Y. Roberfroid, P.N. Chhajed, **T. Dieterle**, L. Joos Zellweger, M. Kohler, S. Maier, D. Miedinger, R. Thurnheer, P. Urwyler, J.M. Tschopp, E. Zuercher, J.D. Leuppi, B. Burnand, I. Peytremann-Bridevaux. Feasibility, acceptability and effectiveness of integrated care for COPD patients: a mixed methods evaluation of a pilot community-based programme. *Swiss Med Wkly* 2017; 147: w14567.
IF: 1.928. **Field:** Medicine, General&Internal.
22. C. Binder, M. Schmid, **T. Dieterle**, H.H. Schäfer. Costs and benefits of diagnostic testing: four ways to improve patient care by purposive use of in-vitro diagnostics. *Swiss Med Wkly* 2017; 147: w14546.
IF: 1.928. **Field:** Medicine, General&Internal.
23. C. Gregoriano, **T. Dieterle**, S. Dürr, I. Arnet, K.E. Hersberger, J.D. Leuppi. Impact of a pharmaceutical intervention to improve adherence of inhaled medication in asthma and COPD patients. *JMIR Res Protoc* 2017; 6: e204.
IF: 4.541. **Field:** Healthcare Sciences&Research.
24. J. Mundwiler, U. Schüpbach, **T. Dieterle**, J.D. Leuppi, A. Schmidt-Trucksäss, D.P. Wolfer, D. Miedinger, S. Brighenti-Zogg. Association of occupational and leisure-time physical activity with aerobic capacity in a working population. *PLoS One* 2017; 12: e0168683.
IF: 2.766. **Field:** Multidisciplinary Sciences.
25. S. Brighenti-Zogg, J. Mundwiler, U. Schüpbach, **T. Dieterle**, D.P. Wolfer, J.D. Leuppi, D. Miedinger. Physical workload and work capacity across occupational groups. *PLoS ONE* 2016; 11: e0154073.
IF: 2.806. **Field:** Multidisciplinary Sciences.

26. U.-P. Rohr, C. Binder, **T. Dieterle**, F. Giusti, C.G.M. Messina, E. Toerien, H. Moch, H.-H. Schäfer. The value of *in vitro* diagnostic testing in medical practice: a status report. PLoS ONE 2016; 11: e0149856.
IF: 2.806. **Field:** Multidisciplinary Sciences.
27. V. Teichgräber, C. Monasterio, K. Chaitanya, R. Boger, K. Gordon, **T. Dieterle**, C. Renner, D. Jäger, S. Bauer. Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro. Adv Med Sci 2015; 60: 264-272.
IF: 1.211. **Field:** Medicine, Research&Experimental.
28. H.-H. Schäfer, L. Filser, U.-P. Rohr, R. Laubender, P. Ruediger, **T. Dieterle**, R. Maitland, C.E. Zaugg. Medical value as a new strategy to increase corporate viability: market chances and limitations in the diagnostic industry. J Entrepren Organiz Manag 2015; 4: 131. doi:10.4172/2169-026X.1000131.
IF: 0.368. **Field:** Management, Business, Decision Science and Finance.
29. H.-H. Schäfer, L. Filser, U.-P. Rohr, C.G.M. Messina, R.P. Laubender, **T. Dieterle**, E. Toerien, C.E. Zaugg. The diagnostic industry in a changing healthcare environment – a focus on the value component. J Management Res 2015; 15: 91-100.
IF: n.a. **Field:** Management, Business, Decision Science and Finance.
30. H.-H. Schäfer, E. Sivukhina, G.-R. Theus, J.D. de Villiers, M. Burnier, G. Noll, U. Lotze, **T. Dieterle**. Patients with non-insulin depending diabetes mellitus and metabolic syndrome are suboptimally treated in Swiss Primary Care. Clin Exp Hypertens 2013; 35: 496-505.
IF: 1.456. **Field:** Peripheral Vascular Disease.
31. C. Mamot, R. Ritschard, A. Wicki, G. Stehle, **T. Dieterle**, L. Bubendorf, C. Hilker, S. Deuster, R. Herrmann, C. Rochlitz. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol 2012; 13: 1234-1241.
IF: 25.117. **Field:** Oncology.
32. H.-H. Schäfer, J.D. de Villiers, I. Sudano, G.-R. Theus, E. Sivukhina, M. Burnier, **T. Dieterle**, G. Noll. Management of hypertension in patients with diabetes mellitus and metabolic syndrome in Swiss primary care. Int J Clin Pract 2012; doi: 10.1111/ijcp.12000.
IF: 2.427. **Field:** Medicine, General&Internal.
33. M.T. Maeder, H. Rickli, M.E. Pfisterer, S. Muzzarelli, P. Ammann, T. Fehr, D. Hack, D. Weilenmann, **T. Dieterle**, S. Kiencke, W. Estlinbaum, H-P. Brunner-La Rocca, for the TIME-CHF Investigators. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. Am Heart J 2012; 163: 407-414.
IF: 4.497. **Field:** Cardiac&Cardiovascular Systems.
34. T. Grussenmeyer, S. Meili-Butz, D. Roth, **T. Dieterle**, M. Brink, B. Winkler, P. Matt, T.P. Carrel, F.S. Eckstein, I. Lefkovits, M.T.R. Grapow. Proteome analysis in cardiovascular pathophysiology using Dahl rat model. J Proteomics 2011; 74: 672-682.
IF: 5.074. **Field:** Biochemical Research Methods.
35. S. Meili-Butz, K. Bühler, D. John, P. Buser, W.W. Vale, K.L. Peterson, M. Brink, **T. Dieterle**. Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension-induced left ventricular hypertrophy and heart failure. Eur J Heart Fail 2010; 12: 797-804.
IF: 4.512. **Field:** Cardiac&Cardiovascular Systems.
36. **T. Dieterle***, J.-P. Sigle*, G. Bengel, G. Kiefer, V. Brenneisen, B. Martina. Cardiovascular risk stratification in unselected primary care patients with newly detected arterial hypertension. Hypertens Res 2010; 33: 607-615 (*equal contribution).
IF: 2.353. **Field:** Peripheral Vascular Disease.
37. P. Blyszczuk, G. Kania, **T. Dieterle**, R.R. Marty, A. Valaperti, C. Berthonneche, T. Pedrazzini, C.T. Berger, S. Dirnhofer, C.M. Matter, J.M. Penninger, T.F. Lüscher, U. Eriksson. MyD88/IL-1 signalling controls cardiac fibrosis and heart failure progression in inflammatory dilated cardiomyopathy. Circ Res 2009; 105: 912-920.
IF: 9.214. **Field:** Cardiac&Cardiovascular Systems.

38. K. Bühler, I. Plaisance, **T. Dieterle***, M. Brink*. The human *urocortin 2* gene is regulated by hypoxia: identification of a hypoxia-responsive element in the 3'-flanking region (*equal contribution). *Biochem J* 2009; 424: 119-127.
IF: 5.155. **Field:** Biochemistry&Molecular Biology.
39. **T. Dieterle***, S. Meili-Butz*, K. Bühler, C. Morandi, D. John, P.T. Buser, J. Rivier, W.W. Vale, K.L. Peterson, M. Brink. Immediate and sustained blood pressure lowering by urocortin 2: a novel approach to antihypertensive therapy? (* equal contribution). *Hypertension* 2009; 53: 739-744.
IF: 6.614. **Field:** Peripheral Vascular Disease.
40. J. Quitt, D. Ryser, **T. Dieterle**, U. Lüscher, B. Martina, P. Tschudi. Does non-medical hospital admission staff accurately triage ED patients? *Eur J Emerg Med* 2009; 16: 172-176.
IF: 0.733. **Field:** Emergency Medicine.
41. T. Grussenmeyer, S. Meili-Butz, **T. Dieterle**, E. Traunecker, T.P. Carrel, I. Levkovits. Quantitative proteome analysis in cardiovascular physiology and pathology. I. Data processing. *J Proteome Res* 2008; 7: 5211-5220.
IF: 5.684. **Field:** Biochemical Research Methods.
42. G. Kania, P. Blyszczuk, A. Valaperti, **T. Dieterle**, B. Leimenstoll, S. Dirnhofer, U. Eriksson. Prominin-1+/CD133+ bone marrow-derived heart-resident cells suppress experimental autoimmune myocarditis. *Cardiovasc Res* 2008; 80: 236-245.
IF: 5.947. **Field:** Cardiac&Cardiovascular Systems.
43. B. Martina, A. Nordmann, **T. Dieterle**, J.P. Sigle, G. Bengel, G. Kiefer, E. Battegay. Impact of baseline echocardiography on treatment outcome in primary care patients with newly detected arterial hypertension. A randomized trial. *Am J Hypertens* 2006; 19: 1150-1155.
IF: 3.116. **Field:** Peripheral Vascular Disease.
44. D. Conen*, **T. Dieterle***, K. Utech, M. Rimner, B. Martina. C-reactive protein and B-type natriuretic peptides in never-treated white coat hypertensives. *Hypertens Res* 2006; 29: 411-415 (*equal contribution).
IF: 3.177. **Field:** Peripheral Vascular Disease.
45. D. Conen, A. Zeller, **T. Dieterle**, B. Martina. C-reactive protein and echocardiography have little impact on risk stratification in never-treated hypertensive patients. *J Hum Hypertens* 2006; 20: 587-592.
IF: 2.960. **Field:** Peripheral Vascular Disease.
46. J. Leuppi*, **T. Dieterle***, I. Wildeisen, B. Martina, M. Tamm, G. Koch, A.P. Perruchoud, B.M. Leimenstoll. Can airway obstruction be estimated by lung auscultation in an emergency room setting? *Respir Med* 2006; 100: 279-285 (*equal contribution).
IF: 2.086. **Field:** Respiratory System.
47. **T. Dieterle**, M. Meyer, Y. Gu, D.D. Belke, E. Swanson, M. Iwatate, J. Hollander, K.L. Peterson, J. Ross Jr., W.H. Dillmann. Gene transfer of a phospholamban-targeted antibody improves intracellular calcium handling and cardiac function in heart failure. *Cardiovasc Res* 2005; 67: 678-688.
IF: 5.283. **Field:** Cardiac&Cardiovascular Systems.
48. **T. Dieterle**, M.M. Schuurmans, W. Strobel, E.J. Battegay, B. Martina. Moderate to severe blood pressure elevation at emergency department entry. Hypertension or normotension? *Am J Emerg Med* 2005; 23: 474-479.
IF: 1.994. **Field:** Emergency Medicine.
49. J. Leuppi*, **T. Dieterle***, G. Koch, B. Martina, M. Tamm, A.P. Perruchoud, I. Wildeisen, B.M. Leimenstoll. Diagnostic value of lung auscultation in an emergency room setting. *Swiss Med Wkly* 2005; 135: 520-524 (*equal contribution).
IF: 1.226. **Field:** Medicine, General&Internal.
50. J. Suarez, D.D. Belke, B. Gloss, **T. Dieterle**, P.M. McDonough, Y.K. Kim, L.L. Brunton, W.H. Dillmann: In vivo adenoviral transfer of sorcin reverses the cardiac contractile abnormalities of diabetic cardiomyopathy. *Am J Physiol Heart Circ Physiol* 2004; 286: H68-H75.
IF: 3.359. **Field:** Cardiac&Cardiovascular Systems.
51. S. Reichlin, **T. Dieterle**, C. Camli, B. Leimenstoll, R. Schönenberger, B. Martina: Initial clinical evaluation of cardiac systolic murmurs in medical emergency patients. *Am J Emerg Med* 2004; 22: 71-75.
IF: 1.823. **Field:** Emergency Medicine.

52. H. Schächinger, **T. Dieterle**, B. Martina, C. Haberthür, P.R. Huber, A. Bock, J. Drewe, K. Gyr. Increased renovascular response to angiotensin II in persons genetically predisposed to arterial hypertension disappears after chronic angiotensin-converting enzyme inhibition. *J Hypertens* 2004; 22: 175-180.
IF: 4.871. **Field:** Peripheral Vascular Disease.
53. Y. Iwanaga, Y. Gu, **T. Dieterle**, C. Presotto, P. del Soldato, K.L. Peterson, E. Ongini, G. Condorelli, J. Ross Jr. A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. *FASEB J* 2004; 18: 587-588.
IF: 6.820. **Field:** Biochemistry&Molecular Biology.
54. Y. Iwanaga, M. Hoshijima, Y. Gu, M. Iwatate, **T. Dieterle**, Y. Ikeda, M.O. Date, J. Chrast, M. Matsuzaki, K.L. Peterson, K.R. Chien, J. Ross Jr. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. *J Clin Invest* 2004; 113: 727-736.
IF: 14.204. **Field:** Medicine, Research&Experimental.
55. M. Meyer, D.D. Belke, S.U. Trost, E. Swanson, **T. Dieterle**, B. Scott, S.P. Carry, P. Ho, W.F. Bluhm, P.M. McDonough, G.J. Silverman, W.H. Dillmann. A recombinant antibody increases cardiac contraction by mimicking phospholamban phosphorylation. *FASEB J* 2004; 18: 1312-1314.
IF: 6.820. **Field:** Biochemistry&Molecular Biology.
56. J. Suarez, B. Gloss, D.D. Belke, Y. Hu, B. Scott, **T. Dieterle**, Y.-K. Kim, M.L. Valencik, J.A. McDonald, W.H. Dillmann. Doxycycline inducible expression of SERCA2a improves calcium handling and reverts cardiac dysfunction in pressure overload-induced cardiac hypertrophy. *Am J Physiol Heart Circ Physiol* 2004; 287: H2164-H2172.
IF: 3.539. **Field:** Cardiac&Cardiovascular Systems.
57. F.N. Kiefer, V.C. Munk, R. Humar, **T. Dieterle**, L. Landmann, E.J. Battegay. A versatile in vitro assay for investigating angiogenesis in the heart. *Exp Cell Res* 2004; 300: 272-282.
IF: 4.007. **Field:** Cell Biology.
58. D. Gubler, B. Martina, M. Arpagaus, **T. Dieterle**: Qualität des Antikoagulationsmanagements bei ambulanten Patienten mit Vorhofflimmern (Anticoagulation in atrial fibrillation: less underuse than expected). *Schweiz Rundschau Med Prax* 2003; 92: 991-995.
IF: n.a.. **Field:** Medicine, General&Internal.
59. M. Yao, T. Dieterle, S.L. Hale, J.S. Dow, L.H. Kedes, K.L. Peterson, R.A. Kloner. Long term outcome of fetal cell transplantation on postinfarction ventricular remodelling and function. *J Mol Cell Cardiol* 2003; 35: 661-670.
IF: 4.954. **Field:** Cardiac&Cardiovascular Systems.
60. M. Iwatate, Y. Gu, **T. Dieterle**, Y. Iwanaga, K.L. Peterson, M. Hoshijima, K.R. Chien, J. Ross, Jr.: In vivo high efficiency transcortical gene delivery and Cre-LoxP gene switching in the adult mouse heart. *Gene Therapy* 2003; 10: 1814-1820.
IF: 5.293. **Field:** Medicine, Research&Experimental.
61. B. Martina, **T. Dieterle**, J.-P. Sigle, C. Surber, E. Battegay. Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomised, double-blind trial. *Cardiology* 2003; 99: 169-170.
IF: 1.127. **Field:** Cardiac&Cardiovascular Systems.
62. **T. Dieterle**, D. Vakil-Gilani, E. Battegay, B. Martina. Reduction of QT dispersion by losartan in patients with mild to moderate hypertension. *Heart Drug* 2002; 2: 9-15.
IF: 0.952 (2002, incorporated in "Cardiology"). **Field:** Cardiac&Cardiovascular Systems.
63. R. Nüesch, K. Schroeder, **T. Dieterle**, B. Martina, E. Battegay: Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. *BMJ* 2001; 323: 142-146.
IF: 6.629. **Field:** Medicine, General&Internal.
64. S.P. Stäubli, S. Reichlin, **T. Dieterle**, B. Leimenstoll, R. Schoenenberger, B. Martina: Community acquired pneumonia - which patients are hospitalised? *Swiss Med Wkly* 2001; 131: 188-192.
IF: n.a.. **Field:** Medicine, General&Internal.

65. B. Martina, **T. Dieterle**, M. Weinbacher, E. Battegay: Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. *Cardiology* 1999; 92: 110-114.
IF: 0.739. **Field:** Cardiac&Cardiovascular Systems.
66. **T. Dieterle**, B. Martina, H. Schächinger, CH. Haberthür, P. Gasser. Effekte einer akuten ACE-Hemmung und von Angiotensin II auf die Hautdurchblutung. Nieren- und Hochdruckkrankheiten 1999; 5: 188-191.
IF: n.a.. **Field:** Medicine, General&Internal.
67. **T. Dieterle**, E. Battegay, B. Bucheli, B. Martina: Accuracy and "range of uncertainty" of oscillometric blood pressure monitors around the upper arm and the wrist. *Blood Press Monit* 1998; 3: 339-346.
IF: 1.455 (2002, earliest IF available). **Field:** Peripheral Vascular Disease.

Übersichtsarbeiten, Positionspapiere (peer-reviewed)

1. **T. Dieterle**. "Deprescribing" von Benzodiazepn-Rezeptor-Antagonisten. *Prim Hosp Care Allg Inn Med* 2022; 22: 380-384.
IF: n.a. **Field:** Medicine (miscellaneous).
2. D. Minoski, **T. Dieterle**. Dyslipidemia and hypertension – brothers in crime?! *Cardiovasc Med* 2021, in press.
IF: n.a. **Field:** Cardiac&Cardiovascular Systems.
3. N. Peters, **T. Dieterle**. Ursachen und klinische Relevanz von Blutdruckvariabilität. *Der informierte Arzt* 2019; 9: 23-26.
IF: n.a. **Field:** Medicine (miscellaneous).
4. F. Bierreth, C. Gregoriano, **T. Dieterle**. Ein erster Blick auf die neuen europäischen Hypertonie-Guidelines. *Prim Hosp Care Allg Inn Med* 2018, 18: 265-269.
IF: n.a. **Field:** Medicine (miscellaneous).
5. Y. Allemann, R. Brenner, M. Burnier, **T. Dieterle**, P. Erne, D. Evéquo, D. Hayoz, F. Muggli, G. Noll, A. Pechère, A. Schönenberger, G. Simonetti, I. Sudano, P. Suter, G. Wuerzner. SPRINT-Studie: Stellungnahme der schweizerischen Hypertonie-Gesellschaft (SHG). Zielblutdruck: vorerst keine Änderung der geltenden Empfehlungen. *Schweiz Med Forum* 2016; 16: 1080-1081.
IF: n.a. **Field:** Medicine (miscellaneous).
6. Y. Allemann, R. Brenner, M. Burnier, **T. Dieterle**, P. Erne, D. Evéquo, D. Hayoz, F. Muggli, G. Noll, A. Pechère, A. Schönenberger, G. Simonetti, I. Sudano, P. Suter, G. Wuerzner. Etude SPRINT: prise de position de la Société Suisse d'Hypertension (SSH). Pression artérielle cible: pour l'instant, pas de modification des recommandations en vigueur. *Forum Med Suisse* 2016; 16: 1080-1081.
IF: n.a. **Field:** Medicine (miscellaneous).
7. **T. Dieterle**. Hypertoniebehandlung nach SPRINT. *info@herz+gefäss* 2016; 06: 25-28.
IF: n.a. **Field:** Cardiac&Cardiovascular Systems.
8. C. Gerhards, C. Gregoriano, C. Moser, **T. Dieterle**, J. Leuppi. Allergisches Asthma und allergische Rhinitis. Evidenzbasiertes Management, das Mittel zum Erfolg? *Ther Umsch* 2016; 73: 349-355.
IF: n.a.. **Field:** Medicine (miscellaneous).
9. C. Gerhards, C. Gregoriano, C. Moser, **T. Dieterle**, J. Leuppi. Umsetzung der COPD-Guidelines in Grundversorgerpraxen. *Ther Umsch* 2016; 73: 327-332.
IF: n.a.. **Field:** Medicine (miscellaneous).
10. C. Gerhards, C. Gregoriano, **T. Dieterle**, J. Leuppi. Asthma. *Schweiz Rundsch Med Prax* 2016; 105: 1099-1102.
IF: 0.175. **Field:** Medicine, General&Internal.
11. C. Gerhards, C. Gregoriano, T. Dieterle, J.D. Leuppi. Die chronisch-obstruktive Lungenerkrankung (COPD) im Überblick. *Schweiz Rundsch Med Prax* 2016; 105: 1151-1155.
IF: 0.175. **Field:** Medicine, General&Internal.
12. **T. Dieterle**. Hypertonie beim betagten Menschen. Bringt die Blutdrucksenkung überhaupt einen Benefit und wie tief soll man gehen? *Hausarzt Praxis* 2016; 3: 14-18.
IF: n.a. **Field:** Medicine (miscellaneous).

13. **T. Dieterle.** Hypertonie beim alten Menschen. Praxis Depesche 2016; 1: 42.
IF: n.a. **Field:** Medicine (miscellaneous).
14. **T. Dieterle.** Nebenwirkungen und Interaktionen häufig eingesetzter kardiologischer Medikamente. Ther Umsch 2015; 72: 702-710.
IF: n.a.. **Field:** Medicine (miscellaneous).
15. H.-H. Schäfer, G.F. Jirikowski, **T. Dieterle**, A. Trachsler, E.A. Kaiser. Bridging the gap: the potential role of CBG in cardiac steroid facilitation. Curr Drug Targets 2015; 16: 1254-1269.
IF: 3.029. **Field:** Pharmacology&Pharmacy.
16. A. Handschin, K. Henny-Fullin, D. Buess, **T. Dieterle.** Kardiovaskuläre Risikostratifizierung bei arterieller Hypertonie und therapeutische Implikationen. Ther Umsch 2015; 72: 361-368.
IF: n.a.. **Field:** Medicine (miscellaneous).
17. D. Buess, K. Henny-Fullin, A. Handschin, J. Leuppi, **T. Dieterle.** Therapieresistente arterielle Hypertonie. Ther Umsch 2015; 72: 389-396.
IF: n.a.. **Field:** Medicine (miscellaneous).
18. A. Handschin, K. Henny-Fullin, D. Buess, J. Leuppi, **T. Dieterle.** Therapie der arteriellen Hypertonie beim betagten Menschen. Ther Umsch 2015; 72: 397-403.
IF: n.a.. **Field:** Medicine (miscellaneous).
19. K. Henny-Fullin, D. Buess, A. Handschin, J. Leuppi, **T. Dieterle.** Hypertensive Krise. Ther Umsch 2015; 72: 405-411.
IF: n.a.. **Field:** Medicine (miscellaneous).
20. **T. Dieterle.** Erectile dysfunction in arterial hypertension. Cardiovasc Med 2014; 17: 82-84.
IF: n.a. **Field:** Cardiac&Cardiovascular Systems.
21. V. Teichgräber, **T. Dieterle.** Arterielle Hypertonie 2013. Was gibt es Neues? Cardiovasc 2013; 5: 4-8.
IF: n.a. **Field:** Cardiac&Cardiovascular Systems.
22. V. Teichgräber, **T. Dieterle.** Medikamenteninteraktionen bei antihypertensiver Therapie. Der informierte Arzt 2013; 6/7: 30-34.
IF: n.a. **Field:** Medicine, General&Internal.
23. H.-H. Schäfer, J.N. de Villiers, I. Sudano, S. Dischinger, G.-R. Theus, **T. Dieterle.** Recommendations for the treatment of hypertension in the elderly and very elderly: a scotoma within international guidelines. Swiss Med Wkly 2012; 142: w13574.
IF: 1.821. **Field:** Medicine, General&Internal.
24. **T. Dieterle.** Blood pressure measurement – an overview. Swiss Med Wkly 2012; 142: w13517.
IF: 1.821. **Field:** Medicine, General&Internal.
25. R. Jeger, **T. Dieterle.** Statins: Have we found the Holy Grail? Swiss Med Wkly 2012; 142: w13515.
IF: 1.821. **Field:** Medicine, General&Internal.
26. H.-H. Schäfer, **T. Dieterle.** Diastolische Herzinsuffizienz. Ther Umsch 2011; 68: 81-87.
IF: n.a.. **Field:** Medicine (miscellaneous).
27. **T. Dieterle**, M. Pfisterer, H. Brunner-LaRocca. Heart failure in the elderly. Aging Health 2008; 4: 137-155.
IF: 0.429. **Field:** Medicine (miscellaneous).
28. A. Zeller, **T. Dieterle**, B. Martina, E. Battegay. Hypertensive Krise. Primary Care 2007; 7: 649-650.
IF: n.a. **Field:** Medicine (miscellaneous).
29. A. Zeller, **T. Dieterle**, B. Martina, E. Battegay. Crise hypertensive. Primary Care 2007; 7: 676-677.
IF: n.a. **Field:** Medicine (miscellaneous).
30. **T. Dieterle**, A. Zeller, B. Martina, E. Battegay. Der hypertensive Notfall (Hypertensive emergency). Schweiz Rundschau Med Prax 2001; 90: 2009-2014.
IF: 0.175. **Field:** Medicine, General&Internal.
31. **T. Dieterle**, M. Solèr. Management der akuten Bronchitis. Schweiz Rundsch Med Prax 1999; 88: 1647-1649.
IF: 0.175. **Field:** Medicine, General&Internal.

WO 2016/066698 A1	Biomarkers for risk prediction of mortality
06-05-2016	Inventors: R. Latini, S. Masson, D. Block, C. Zaugg, T. Dieterle , E. Kaiser, J. Karl, V. Rolny, U.-H. Wienhues-Thelen

WO 2016/062709 A1 28-04-2016	Biomarkers and methods of prediction Inventors: T. Dieterle , E. Niesor, R. Kientsch-Engel, H. Klima, F. Model, G. Bucklar, V. Rolny
WO 2015/144767 A1 01-10-2015	IGFBP7 for diagnosing diastolic dysfunction Inventors: J. Karl, U.-H. Wienhues-Thelen, D. Block, C. Zaugg, H.P. Brunner, J. Januzzi, A. Ziegler, J. Braz, T. Dieterle , E. Kaiser
WO 2015/113889 A1 06-08-2015	Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides Inventors: D. Block, H.-P. Brunner, U.-H. Wienhues-Thelen, C. Zaugg, T. Dieterle , C. Mitchell, J. Ubby, S. Sanders-van Wijk
WO 2015/110624 A1 30-07-2015	Prediction of postpartum HELLP syndrome, postpartum eclampsia or postpartum preeclampsia Inventors: M. Hund, T. Dieterle , O. Lapaire
WO 2014/028469 A2 CA 2920066 A1 05-03-2016	Marker for statin treatment stratification in heart failure Inventors: D. Block, H.-P. Beunier, T. Dieterle , U.-H. Wienhues-Thelen, C. Zaugg, A. Ziegler

Unabhängig begutachtete Abstracts und Konferenzbeiträge

1. J.M. Kröpfl, D. Honeycutt, H.-J. Gruber, R. Schoch, B.A. Gasser, M. Brink, T. Dieterle, A. Schmidt-Trucksäss, N. Kränkel. Minimal elevation of mononuclear cell-intrinsic microRNA-21 is linked to circulating progenitor cell mobilization during acute exercise in HFpEF. Abstract accepted for Moderated Poster Presentation at the ESC Preventive Cardiology 2025, Milan, Italy.
2. M. Boesing*, F. Bierreth*, S. Züsli, L. Kleinsorge, K. Abig, S. Maier, J. D. Leuppi, T. Dieterle (*equal contribution). Clinical effects and safety of NT-proBNP-guided therapy in patients hospitalized for acute decompensated heart failure. *Eur J Heart Fail* 2021; 23(Suppl.2): 214-215. doi: 10.1002/ejhf.2297.
3. M. Boesing*, F. Bierreth*, S. Züsli, L. Kleinsorge, K. Abig, S. Maier, J. D. Leuppi, T. Dieterle (*equal contribution). Point Of Care with serial NT-proBNP measurement in patients with acute decompensated heart failure as a tool for therapy monitoring during hospitalization: The POC-HF study. *Cardiovasc Med* 2021 (Suppl.): 44S.
4. M. Boesing*, A. Deiseroth*, L. Streese, T. Dieterle°, Henner Hanssen° (*, ° equal contributions). High intensity interval training alters ventricular-arterial coupling in a cardiovascular risk population: echocardiographic data from the EXAMIN AGE cohort. *Prim Hosp Care Allg Inn Med* 2021;21 (Suppl. 11): 19S.
5. M. Boesing, F. Bierreth, S. Züsli, L. Kleinsorge, K. Abig, S. Maier, J. D. Leuppi, T. Dieterle (*equal contribution). Serial Point Of Care NT-proBNP measurement in patients with acute decompensated heart failure may lead to more pronounced up-titration of prognostically relevant heart failure therapies. *Prim Hosp Care Allg Inn Med* 2021;21 (Suppl. 11): 44S.
6. M. Boesing, C. Gregoriano, A.E. Minder, C. Abshagen, S. Dahl, T. Dieterle, F. Eicher, A.B. Leuppi-Taegtmeyer, D. Miedinger, E. Wirz, J.D. Leuppi. Predictors for unplanned readmissions within 18 days after hospital discharge: A retrospective cohort study. *Prim Hosp Care Allg Inn Med* 2021;21 (Suppl. 11): 93S.
7. C. Degen, K. Glaettli, F. Riede, T. Dieterle, G. Leibundgut. Assessment of hand vein collapse level as a new and non-invasive method to measure central venous pressure. *Hospitalis* 2019; 89: 6S.
8. G. Leibundgut, S. Hubeli, A. Souza, H. Lehner, S. Brighenti-Zogg, C. Gregoriano, F. Bierreth, P. Hasler, A. Hammerer-Lercher, M. Brändle, L. Gabutti, A. Leuppi-Taegtmeyer, J. Muser, C. Schraner, J. Leuppi, T. Dieterle. Clinical research from multi-modality data sources - the CREATE project. *Prim Hosp Care Allg Inn Med* 2019; 19 (Suppl. 10): P127.
9. C. Gregoriano, T. Dieterle, A.-L. Breitenstein, S. Dürr, A. Baum, S. Giezendanner, S. Maier, A. Leuppi-Taegtmeyer, I. Arnet, K.E. Hersberger, J.D. Leuppi. Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial. *Prim Hosp Care Allg Inn Med* 2019; 19 (Suppl. 10): P37.
10. A. Naduvilekoot, J. Leuppi, B. Martina, P. Tschudi, A. Zeller, T. Dieterle. Discrepancies in cardiovascular risk stratification in hypertensive patients – Results from the Swiss Hypertension Cohort Study (HCCH). *J Hypertens* 2018; 36: E115.
11. J. Marmy, J. Dietrich, T. Dieterle, J. Leuppi. COPD GOLD 2017 guidelines in Swiss pulmologists and general practitioners. *ERJ* 2018; 52: PA911; doi: 10.1183/13993003.congress-2018.PA911
12. C. Gregoriano, A.-L. Flamm, S. Maier, S. Dürr, T. Dieterle, I. Arnet, K.E. Hersberger, J.D. Leuppi. How do patients adhere to chronic treatment of pulmonary diseases? Data from the Adherence-Trial. Meeting of the European Society for Patient Adherence, Compliance and Persistence, Budapest, 2017.

13. E. Thesenvitz, A. Naduvilekoot, S. Züsli, S. Maier, T. Jendricke, J. Leuppi, T. Dieterle. Predictors of COPD exacerbation – Data analysis of the Swiss COPD Cohort Study (SCCS). *Wien Klin Wochenschr* 2017; 129: 754.
14. E. Thesenvitz, S. Züsli, A. Naduvilekoot, S. Maier, T. Jendricke, J. Leuppi, T. Dieterle. Combination therapy in the Swiss COPD Cohort Study – An interim analysis. *Wien Klin Wochenschr* 2017; 129: 754.
15. B. Janisch, S. Giezendanner, K. Henny-Fullin, D. Buess, A. Handschin, A. Zeller, J.D. Leuppi, T. Dieterle. The relation of arterial hypertension and target organ damage in the Swiss Hypertension Cohort Study. *Journal of Hypertension* 35:p e271, September 2017. doi: 10.1097/01.hjh.0000523786.70737.00.
16. E. Thesenvitz, S. Brighenti-Zogg, J. Mundwiler, B. Janisch, J.D. Leuppi, T. Dieterle. High-intensity interval training as treatment strategy for heart failure patients with preserved ejection fraction: a protocol proposal for a randomized controlled trial. *European Meeting on Hypertension and Cardiovascular Prevention, Milano, 2017.*
17. S. Kind, J. Mundwiler, U. Schüpbach, J. Leuppi, T. Dieterle, S. Brighenti-Zogg. Metabolic profile and predictors of physical fitness in a Swiss working population. *European Meeting on Hypertension and Cardiovascular Prevention, Milano, 2017.*
18. S. Giezendanner, K. Henny-Fullin, D. Buess, A. Handschin, P. Tschudi, T. Dieterle, A. Zeller. Cardiovascular risk factors in a hypertensive population in primary care in Switzerland. *European Meeting on Hypertension and Cardiovascular Prevention, Milano, 2017.*
19. E. Thesenvitz, S. Brighenti-Zogg, J. Mundwiler, B. Janisch, J.D. Leuppi, T. Dieterle. High-intensity interval training as treatment strategy for heart failure patients with preserved ejection fraction: a protocol proposal for a prospective single-blind randomized controlled trial. *Prim Hosp Care* 2017 (Suppl. 7); 17: 70S.
20. B. Janisch, S. Giezendanner, K. Henny-Fullin, D. Buess, A. Handschin, A. Zeller, J.D. Leuppi, T. Dieterle. The relation of blood pressure and target organ damage in the Swiss hypertension cohort study. *Prim Hosp Care* 2017 (Suppl. 7); 17: 81S.
21. C. Gregoriano, S. Henny-Reinalter, S. Maier, A.-L. Flamm, T. Dieterle, I. Arnet, K.E. Hersberger, J.D. Leuppi. How do patients adhere to chronic treatment of pulmonary diseases? Preliminary data from a randomized controlled trial. *Swiss Societies of Cardiology, Cardiac and Thoracic Surgery, and Pneumology, Lausanne, 2016.*
22. S. Henny, T. Dieterle, T. Brack, M. Brutsche, C. Clarenbach, A. Egli, I. Heijnen, S. Irani, M. Frey, N. Sievi, R. Thurnheer, M. Trendelenburg, M. Kohler, J. Leuppi. Value of clinical characteristics as predictors of frequent exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS). *Swiss Societies of Cardiology, Cardiac and Thoracic Surgery, and Pneumology, Lausanne, 2016.*
23. S. Henny, T. Dieterle, T. Brack, M. Brutsche, C. Clarenbach, A. Egli, I. Heijnen, S. Irani, M. Frey, N. Sievi, R. Thurnheer, M. Trendelenburg, M. Kohler, J. Leuppi. Interferon-lambda-genotype GG and IgG2 predict frequent COPD exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS). *Swiss Societies of Cardiology, Cardiac and Thoracic Surgery, and Pneumology, Lausanne, 2016.*
24. U. Schüpbach, J. Mundwiler, T. Dieterle, J.D. Leuppi, D. Miedinger, S. Brighenti-Zogg. The association of blood pressure and body composition measures with maximal aerobic capacity in a Swiss working population. *European Meeting on Hypertension and Cardiovascular Prevention, Paris, 2016.*
25. D. Buess, S. Giezendanner, K. Henny-Fullin, A. Handschin, P. Tschudi, B. Martina, A. Zeller, T. Dieterle. Compliance with ESH/ESC guidelines for arterial hypertension in Swiss primary care: pharmacological therapy. *European Meeting on Hypertension and Cardiovascular Prevention, Paris, 2016.*
26. D. Buess, T. Dieterle, J.D. Leuppi, A. Zeller, B. Martina, P. Tschudi, K. Henny-Fullin, S. Giezendanner. Fixed-dose combinations of antihypertensive drugs may not improve blood pressure control compared to free drug combinations: findings from the Swiss Hypertension Cohort Study. *European Meeting on Hypertension and Cardiovascular Prevention, Paris, 2016.*
27. S. Henny, T. Dieterle, T. Brack, M.H. Brutsche, C. Clarenbach, A. Egli, I. Heijnen, S. Irani, M. Frey, N. Sievi, R. Thurnheer, M. Trendelenburg, M. Kohler Malcom, J. Leuppi Jörg. Clinical characteristics of patients with frequent exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS). *Swiss Society of General Internal Medicine Basel 2016.*
28. S. Henny, T. Dieterle, T. Brack, M.H. Brutsche, C. Clarenbach, A. Egli, I. Heijnen, S. Irani, M. Frey, N. Sievi, R. Thurnheer, M. Trendelenburg, M. Kohler Malcom, J. Leuppi Jörg. IgG2 and IFN-lambda-genotype GG predict frequent COPD exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS). *Swiss Society of General Internal Medicine, Basel, 2016.*
29. Adherence of lung patients to inhalative medical treatment: preliminary data from a randomized controlled trial. *Swiss Society of General Internal Medicine, Basel, 2016.*
30. Compliance with ESH/ESC guidelines for arterial hypertension in swiss primary care: pharmacological therapy. *Swiss Society of General Internal Medicine, Basel, 2016.*
31. Fixed-dose combinations of antihypertensive drugs may not improve blood pressure control compared to free drug combinations – findings from the Swiss Hypertension Cohort Study. *Swiss Society of General Internal Medicine, Basel, 2016.*

32. U. Schüpbach, J. Mundwiler, T. Dieterle, J.D. Leuppi, D. Miedinger, S. Brighenti-Zogg. The association of blood pressure and body composition measures with maximal aerobic capacity in a Swiss working population. Swiss Society of General Internal Medicine, Basel, 2016.
33. A. Handschin, A. Zeller, P. Tschudi, B. Martina, T. Dieterle. How compliant are general practitioners with the European Society of Hypertension risk stratification guidelines? Preliminary data from the Swiss Hypertension Cohort Study. European Meeting on Hypertension and Cardiovascular Prevention, Milan, 2015.
34. Handschin, A. Zeller, P. Tschudi, B. Martina, J. Leuppi, T. Dieterle. Cardiovascular risk profile and blood pressure control in treated hypertensive patients - an analysis from the Swiss Hypertension Cohort Study. Swiss Society of Internal Medicine Basel 2015.
35. Handschin, A. Zeller, P. Tschudi, B. Martina, J. Leuppi, T. Dieterle. Compliance with the European Society of Hypertension risk stratification guidelines in primary care - data from the Swiss Hypertension Cohort Study. Swiss Society of Internal Medicine, Basel, 2015.
36. S. Zogg, J. Mundwiler, U. Schüpbach, T. Dieterle, D. Miedinger, J.D. Leuppi. Physical activity and energy expenditure across occupational categories. Swiss Society of Internal Medicine, Basel, 2015.
37. J. Mundwiler, S. Zogg, U. Schüpbach, T. Dieterle, D. Miedinger, J.D. Leuppi. Association of occupational and leisure time physical activity with aerobic capacity in a working population. Swiss Society of Internal Medicine, Basel, 2015.
38. Gregoriano, S. Henny-Reinalter, A. Handschin, A.-L. Flamm, T. Dieterle, I. Arnet, K.E. Hersberger, J.D. Leuppi. How do patients adhere to chronic treatment of pulmonary diseases? Baseline data from the Adherence Study. Swiss Society of Pneumology, Lugano, 2015.
39. S. van Wijk, V. van Empel, M.T. Maeder, S. Muzzarelli, U. Jeker, T. Dieterle, R. Handschin, S. Kiencke, M.E. Pfisterer, H.P. Brunner-LaRocca. Biomarkers in heart failure with preserved versus reduced ejection fraction. *Eur J Heart Fail* 2014; 2 (Suppl. 2): 92.
40. Rochlitz, R. Ritschard, B. Vogel, T. Dieterle, L. Bubendorf, C. Hilker, S. Deuster, R. Herrmann, C. Mamot. A phase I-study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors. *Onkologie*; 34 (Suppl. 6): 109.
41. Mamot, R. Ritschard, B. Vogel, T. Dieterle, L. Bubendorf, C. Hilker, S. Deuster, R. Herrmann, C. Rochlitz. A phase I-study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors. *J Clin Oncol* 2011; 29 (Suppl. S): Abstract 3029.
42. S. Meili-Butz, K. Bühler, D. John, T. Dieterle. Functional effects of longer-term application of urocortin 2 compared to enalapril in an animal model of severe heart failure. *Kardiovask Med* 2011; 14 (Suppl. 20): 57S.
43. M. Ammon, R. Buechel, K. Glatz, T. Dieterle, P. Buser, O. Pfister. No diagnostic value of high sensitive troponin T as a marker for cardiac allograft rejection in long-term cardiac transplant survivors. *Kardiovask Med* 2011; 14 (Suppl. 20): 61S.
44. S. Meili-Butz; K. Buehler; D. John; W. W. Vale; K. L. Peterson; T. Dieterle. Urocortin 2 versus enalapril: Effects of longer-term administration on left ventricular function and survival in rats with severe heart failure. *Eur J Heart Fail Suppl* 2011; 10: S14.
45. M.T. Maeder, H. Rickli, P. Ammann, D. Hack, D. Weilenmann, T. Dieterle, S. Kiencke, W. Estlinbaum, M. Pfisterer, H.P. Brunner-LaRocca. Worsening renal failure in elderly patients with heart failure on intense medical therapy: clinical predictors and prognostic impact. *Eur Heart J* 2010; 31 (Suppl. 1): 16.
46. S. Meili-Butz, K. Bühler, P. Buser, M. Brink, T. Dieterle. Apelin and Kisspeptin: Potential new biomarkers for congestive heart failure? Abstract Cardiovascular Research and Clinical Implications 2010, Muntelier.
47. Kaiser, B. Martina, P. Tschudi, T. Dieterle, for the Swiss Hypertension Cohort Study Investigators. Office, ambulatory and home blood pressure measurements in Swiss primary care patients with arterial hypertension: how do they correlate? Abstract WONCA 2010, Malaga.
48. S. Meili-Butz, K. Bühler, P. Buser, M. Brink, T. Dieterle. Potential new biomarkers for congestive heart failure: evaluation of apelin and kisspeptin in an animal model of hypertension-induced heart failure. *Eur J Heart Fail Suppl*. 2010; 9: S206.
49. S. Meili-Butz, K. Bühler, D. John, P. Buser, W.W. Vale, K.L. Peterson, M. Brink, T. Dieterle. Longer-term administration of urocortin 2 in experimental severe heart failure – Effects on left ventricular function and survival. Abstract Biovalley 2010, Basel.
50. S. Meili-Butz, K. Bühler, D. John, C. Morandi, P. Buser, W.W. Vale, K.L. Peterson, M. Brink, T. Dieterle. Effects of chronic administration of Urocortin 2 on hemodynamics and survival in rats with severe heart failure. *Circulation* 2009; 120: S867.
51. S. Meili-Butz, D. John, K. Bühler, P. Buser, M. Brink, T. Dieterle. Chronic Administration of Urocortin 2 in Hypertension-Induced Left Ventricular Hypertrophy: Effects on Calcium Handling and Hemodynamics. *Circulation* 2009; 120: S868.
52. K. Buehler, I. Plaisance, T. Dieterle, M. Brink. Hypoxia inducible factor 1 (HIF1) enhances transcription of the human urocortin 2 gene. *Eur J Heart Fail Suppl*. 2009; 8(2): Abstract 387.

53. S. Meili-Butz, D. John, P. Buser, M. Pfisterer, W.W. Vale, K.L. Peterson, M. Brink, T. Dieterle. Beneficial effects of urocortin 2 on left ventricular function and ventricular fibrillation threshold in failing rat hearts. *Eur J Heart Fail Suppl.* 2009; 8(2): Abstract 321.
54. S.P. Hauselmann, B.I. Rosc-Schluter, S. Meili-Butz, I. Plaisance, M. Brink, T. Dieterle, O. Pfister, G.M. Kuster. Beta1-integrin up-regulation is associated with adaptive remodeling and mediated via Rac1/reactive oxygen species in cardiomyocytes. *Eur J Heart Fail Suppl.* 2009; 8(2): Abstract.
55. K. Bühler, I. Plaisance, T. Dieterle, M. Brink. Transcriptional regulation of the human urocortin 2 gene by hypoxia-inducible factor 1. *Kardiovask Med* 2009; 12 (Suppl. 17): 41S.
56. S. Meili-Butz, D. John, K. Bühler, M. Pfisterer, P. Buser, W.W. Vale, K.L. Peterson, M. Brink, T. Dieterle. Prevention of heart failure by urocortin 2 is accompanied by beneficial effects on intracellular calcium levels in an animal model of hypertensive heart disease. *Kardiovask Med* 2009; 12 (Suppl. 17): 30S.
57. S. Meili-Butz, D. John, P. Buser, M. Pfisterer, W.W. Vale, K.L. Peterson, M. Brink, T. Dieterle. Acute administration of urocortin 2 improves left ventricular function and increases ventricular fibrillation threshold in failing rat hearts. *Kardiovask Med* 2009; 12 (Suppl. 17): 53S.
58. S.P. Häuselmann, B.I. Rosc-Schlüter, V. Lorenz, S. Meili-Butz, D. John, I. Plaisance, M. Brink, T. Dieterle, O. Pfister, G.M. Kuster. Rac1 and superoxide mediate β 1-integrin up-regulation in cardiomyocytes inherent to compensated hypertrophy. *Kardiovask Med* 2009; 12 (Suppl. 17): 37S.
59. S. Meili-Butz*, M. Studer*, D. John, C. Morandi, M. Pfisterer, P. Buser, W.W. Vale, K.L. Peterson, M. Brink, T. Dieterle. Chronic administration of urocortin 2 prevents the development of heart failure in an animal model of hypertensive heart disease. (* equal contribution) *Circulation* 2008; 118: S_881.
60. K. Bühler, T. Dieterle, M. Brink. Hypoxia enhances the expression of human Urocortin 2 via HIF-1. *Eur Heart J* 2008; 29 (Abstr. Suppl.): 111.
61. K. Bühler, T. Dieterle, M. Brink. The role of hypoxia in the regulation of human urocortin 2 expression. *Kardiovask Med* 2008; 11 (Suppl. 16): 7S.
62. S. Meili-Butz, D. John, P. Buser, M. Pfisterer, W. Vale, K. Peterson, M. Brink, T. Dieterle. Acute antiarrhythmic effects of urocortin 2 in isolated perfused rat hearts. *Kardiovask Med* 2008; 11 (Suppl. 16): 23S.
63. M. Studer, S. Meili-Butz, C. Morandi, D. John, K. Bühler, M. Pfisterer, P. Buser, W. Vale, K. Peterson, M. Brink, T. Dieterle. Chronic administration of urocortin 2 prevents the development of heart failure in an animal model of hypertensive heart disease. *Kardiovask Med* 2008; 11 (Suppl. 16): 24S.
64. T. Dieterle*, S. Meili-Butz*, K. Bühler, C. Morandi, D. John, M. Pfisterer, P. Buser, W.W. Vale, K.L. Peterson, M. Brink. Immediate and sustained blood pressure lowering by CRF-receptor stimulation: a novel approach to antihypertensive therapy? (* equal contribution) *Circulation* 2007; 116: II_124.
65. T. Dieterle, S. Meili-Butz, K. Bühler, C. Morandi, D. John, M. Pfisterer, P. Buser, K.L. Peterson, M. Brink. Sustained blood pressure lowering by CRF-receptor stimulation: a novel approach to antihypertensive therapy? *Kardiovask Med* 2007; 10 (Suppl. 13): 17S.
66. Kania, P. Blyszczuk, A. Valaperti, S. Dirnhofer, T. Dieterle, U. Eriksson. Prominin-1+ bone marrow derived heart-resident cells suppress experimental autoimmune myocarditis. *Kardiovask Med* 2008; 11 (Suppl. 16): 6S.
67. P. Blyszczuk, R. Marty, G. Kania, A. Valaperti, T. Dieterle, U. Eriksson. Progression of myocarditis to myocardial fibrosis critically depends on sequential activation of MyD88 and IL-1 signalling pathways. *Kardiovask Med* 2008; 11 (Suppl. 16): 6S.
68. L. Jörg, B. Schär, T. Dieterle, S. Osswald, C. Sticherling. Prevalence of severely impaired ejection fraction after percutaneous coronary intervention. *Kardiovask Med* 2007; 10 (Suppl. 13): 44S.
69. M. Coenen, M. Kühne, P. Ammann, T. Dieterle, B. Schär, C. Sticherling, S. Osswald. Long-term outcome of cardiac resynchronisation therapy: reverse mechanical remodeling of the heart. *Heart Rhythm* 2006; 3: S335
70. T. Dieterle, Y. Gu, W. Vale, M. Hoshijima, M. Pfisterer, P.T. Buser, K. Peterson. Urocortin II: potential to improve left ventricular function in beta-adrenergic agonist resistant congestive heart failure? *Eur Heart J* 2006; 27: 483.
71. S. Meili-Butz, C. Morandi, N. Butz, D. John, M. Pfisterer, P.T. Buser, M. Brink, T. Dieterle. First evidence of up-regulation of urocortin II in hypertension-induced left ventricular hypertrophy in rats. Abstract "Annual meeting of the Swiss Society of Cardiology", Basel, 2006.
72. T. Dieterle, Y. Gu, W. Vale, M. Hoshijima, M. Pfisterer, P.T. Buser, K. Peterson. Urocortin II: potential to improve left ventricular function in beta-adrenergic agonist resistant congestive heart failure? Abstract "Annual meeting of the Swiss Society of Cardiology", Basel, 2006.
73. S. Meili-Butz, C. Morandi, N. Butz, D. John, P. Buser, M. Brink, T. Dieterle. The CRF-related peptides: potential new markers for congestive heart failure. Abstract "The Swiss Cardiovascular Research and Training Network Annual Meeting", Bern, 2006.

74. T. Dieterle, Y. Gu, T. Bale, W.W. Vale, M. Hoshijima, K.R. Chien, M. Pfisterer, P. Buser, K.L. Peterson. Hemodynamic effects of urocortin II in heart failure in vivo: comparison to beta-adrenergic stimulation. *Circulation* 2005.
75. Murigande, I. Plaisance, T. Dieterle, C. Morandi, M. Brink. Differential regulation of p38 MAPK by insulin, IGF-I, and TNF- α in adult rat cardiomyocytes. *Kardiovask Med* 2005; 8, Suppl. 10: S19 (P30).
76. T. Dieterle, Y. Gu, T. Bale, W.W. Vale, M. Hoshijima, K.R. Chien, M. Pfisterer, P. Buser, K.L. Peterson. Superiority of Urocortin II over dobutamine to improve contractility and global function in heart failure in vivo. *Kardiovask Med*; 8, Suppl. 8: S60 (P224).
77. Conen, T. Dieterle, M. Rimner, K. Utech, M. Pfisterer, B. Martina. Never-treated white coat hypertensives do have increased concentrations of B-type natriuretic peptide and C-reactive protein. *Kardiovask Med*; 8, Suppl. 8: S82 (P284).
78. M. Coenen, B. Kaufmann, P. Ammann, T. Dieterle, A. Linka, P. Buser, B. Schär, C. Huldi, C. Sticherling, S. Osswald. Long-term effects of cardiac resynchronisation therapy: reverse mechanical remodeling of the heart. *Kardiovask Med*; 8, Suppl. 8: S42 (P163).
79. P.C. Burger, A. Bernheim, T. Dieterle, R. Handschin, A. Linka, R. Schindler, W. Kiowski, H. Rickli, H.P. Brunner-La Rocca. Matrix metalloproteinase 2, a predictor of hemodynamic worsening in patients with congestive heart failure. *Kardiovask Med*; 8, Suppl. 8: S59 (P222).
80. T. Dieterle, D.D. Belke, M. Meyer, P. Buser, M. Pfisterer, K.L. Peterson, W.H. Dillmann, J. Ross Jr.. A new experimental tool for the analysis of functional effects of gene therapy approaches for the treatment of heart failure. *Kardiovask Med*; 7, Suppl. 6: S37 (P168).
81. T. Dieterle, D.D. Belke, T. Bale, W.W. Vale, M. Hoshijima, K.R. Chien, M. Pfisterer, P. Buser, W.H. Dillmann, K.L. Peterson. Effects of Urocortin II in isolated cardiac myocytes from the muscle LIM protein knock-out mouse, a model for dilated cardiomyopathy: bypass of blunted β -adrenergic response in heart failure. *Circulation* 2004; 110, Suppl. III: 2810.
82. T. Dieterle, M. Meyer, Y. Gu, H. Ashikaga, E. Swanson, M. Iwatate, K.L. Peterson, W.H. Dillmann, J. Ross Jr. Gene Transfer of Contractilin, a Recombinant Inotropic Antibody-Based Protein, Improves Cardiac Function in the BIO 14.6 Hamster. *J Am Coll Cardiol* 2003; 41 (6 suppl. A): 864-1.
83. Ashikaga, M. Barr, L. J. Hsu, T. Dieterle, M. Hoshijima, J. Ross Jr., K.R. Chien, J.W. Covell, F.J. Villareal. Effects of gene transfer of urokinase-type plasminogen activator on extracellular matrix and ventricular remodelling in swine. *J Am Coll Cardiol* 2003; 41 (6 suppl. A): 864-2.
84. J.D. Leuppi, T. Dieterle, G. Koch, I. Meisinger-Wildeisen, B. Martina, M. Tamm, A.P. Perruchoud, B. Leimenstoll. Value of lung auscultation under emergency room conditions. Abstract, Meeting of the American Thoracic Society, 2003.
85. T. Dieterle, D.D. Belke, M. Hoshijima, K.R. Chien, T. Bale, W.W. Vale, W.H. Dillmann, K.L. Peterson. Urocortin II improves intracellular calcium handling and contractility in isolated cardiac myocytes from wild-type and muscle LIM protein knock-out mice. *Circulation* 2003; 108, Suppl. IV: 1599.
86. J. Suarez, Y.-K. Kim, B. Scott, B. Gloss, T. Dieterle, D.D. Belke, W.H. Dillmann. Inducible overexpression of sarcoplasmic reticulum Ca²⁺-ATPase (SERCA2a) in the heart of transgenic mice reverts pressure overload-induced contractile dysfunction. *Circulation* 2003; 108, Suppl. IV: 727.
87. T. Dieterle, Y. Gu, H. Ashikaga, E. Swanson, M. Iwatate, K.L. Peterson, W.H. Dillmann, J. Ross Jr.. Effects of a gene transfer of Contractilin, a recombinant inotropic antibody based protein, on cardiac function in the BIO 14.6 hamster. Abstract, La Jolla-Rome-Yamaguchi Research Conferences on Cardiac Function, La Jolla, CA, USA, 2002.
88. J.-P. Sigle, A. Christ, T. Dieterle, E. Battegay, B. Martina. Korrelation von BNP mit 24-Stunden-Blutdruck bei erhöhten Praxis-Blutdruckwerten. *Swiss Medical Forum* 2002, Suppl.8.: P256.
89. T. Dieterle, J. Sigle, G. Kiefer, G. Bengel, E. Battegay, B. Martina. Should early echocardiography be used to guide antihypertensive treatment? A randomised study on the outcome after 6 months. *J Hypertens* 2002; 20, Suppl. 4: P1337.
90. J.D. Leuppi, I. Meisinger-Wildeisen, G. Koch, T. Dieterle, B. Martina, M. Tamm, A.P. Perruchoud, B. Leimenstoll. Estimation of airway obstruction by auscultation under emergency room condition. Abstract, Meeting of the European Respiratory Society, Stockholm, Sweden, 2002.
91. F.N. Kiefer, T. Dieterle, R. Humar, S. Neysari, W. Li, E.J. Battegay. Development of an assay of angiogenesis in vitro of the heart. *J Vasc Res* 2002; 39 (S1): 64(PAN17).
92. Bengel, G. Kiefer, T. Dieterle, E. Battegay, B. Martina. Left ventricular mass in general medical outpatients with newly detected hypertension. Abstract, International Symposium on Angiotensin II receptor Antagonism, Monaco, 2001.
93. S. Reichlin, T. Dieterle, S. Geigy, B. Leimenstoll, R. Schoenenberger, B. Martina. Good reproducibility of the loudness of systolic murmurs. Abstract, 3rd Congress of the European Federation of Internal Medicine, Edinburgh, Scotland, 2001.
94. B. Leimenstoll, S. Reichlin, S.P. Stäubli, T. Dieterle, R. Schoenenberger, B. Martina. Predictors for hospitalization of low-risk patients with community acquired pneumonia. Abstract, 3rd Congress of the European Federation of Internal Medicine, Edinburgh, Scotland, 2001.

95. B. Leimenstoll, S. Reichlin, S. Stäuble, R. Schoenenberger, T. Dieterle, B. Martina. Welche Niedrigrisiko-Patienten mit ambulant erworbener Pneumonie werden hospitalisiert? Abstract, Annual Meeting of the Swiss Society of Internal Medicine, Lausanne, 2001.
96. Gubler, M. Arpagaus, T. Dieterle, B. Martina. Welche Patienten mit Vorhofflimmern werden trotz Indikation nicht antikoaguliert? Abstract, Annual Meeting of the Swiss Society of Internal Medicine, Lausanne, 2001.
97. T. Handschin, T. Dieterle, E. Battegay, B. Martina, A. Schicker. Langzeitwirkung nach Absetzen von Telmisartan auf Blutdruck und Plasma-Renin-Aktivität bei Patienten mit arterieller Hypertonie. Abstract, Annual Meeting of the Swiss Society of Internal Medicine, Lausanne, 2001.
98. G. Kiefer, G. Bengel, T. Dieterle, V. Brenneisen, E. Battegay, B. Martina. Isoliert erhöhter systolischer oder diastolischer Blutdruck bei Erstmessung ist nicht prädiktiv für eine Weisskittelhypertonie. Abstract Annual Meeting of the Swiss Society of Internal Medicine, Lausanne, 2001.
99. T. Dieterle, G. Kiefer, G. Bengel, E. Battegay, B. Martina. Do JNC VI office blood pressure stages predict definite hypertension in general medical outpatients? J Hypertens 2001; 19, Suppl. 2: P1.153.
100. T. Dieterle, G. Kiefer, G. Bengel, E. Battegay, B. Martina. Echocardiography should be performed in all patients without signs of target organ damage in routine evaluation of hypertension. J Hypertens 2001, Suppl. 2: P3.27.
101. G. Kiefer, G. Bengel, T. Dieterle, E. Battegay, B. Martina. Isolated systolic or diastolic office blood pressure elevation at first consultation does not predict white coat hypertension. J Hypertens 2001; 19, Suppl. 2: P2.5.
102. T. Handschin, T. Dieterle, A. Schicker, E. Battegay, B. Martina. Persisting reduction of blood pressure and increase of plasma Renin activity after discontinuation of Telmisartan treatment in hypertensive patients. J Hypertens 2001; 19, Suppl. 2: P2.196.
103. Vakil-Gilani, T. Dieterle, E. Battegay, B. Martina. Reproduzierbarkeit von QT-Dispersion und Cornell-Produkt im Ruhe-EKG bei Patienten mit Hypertonie. Schweiz Med Wochenschr 2000; 130, Suppl. 115: P45.
104. T. Dieterle, M. Schuurmans, C. Kaufmann, E. Battegay, B. Martina. Wertigkeit erhöhter Blutdruckwerte bei akuten Notfällen. Schweiz Med Wochenschr 2000; 130, Suppl. 115: P46.
105. S. Geigy, S. Reichlin, T. Dieterle, B. Leimenstoll, R. Schoenenberger, B. Martina. Hohe Übereinstimmung bei der Beurteilung der Lautstärke eines Systolikums. Schweiz Med Wochenschr 2000; 130, Suppl. 115: P90.
106. T. Dieterle, M. Schuurmans, C. Kaufmann, E. Battegay, B. Martina. Value of elevated blood pressure in an emergency department for the detection of arterial hypertension. J Hypertens 2000; 18, Suppl. 2: P 1.103.
107. T. Dieterle, D. Vakil-Gilani, E. Battegay, B. Martina. Losartan reduces QT-dispersion in patients with mild-to-moderate hypertension. J Hypertens 2000; 18, Suppl. 2: P 1.194.
108. T. Dieterle, D. Vakil-Gilani, E. Battegay, B. Martina. Reduktion der QT-Dispersion durch Losartan bei Patienten mit leichter bis mittelschwerer Hypertonie. Abstract, Jahrestagung der Deutschen Liga zu Bekämpfung des hohen Blutdrucks, Heidelberg, 2000.
109. Bengel, G. Kiefer, T. Dieterle, E. Battegay, B. Martina. Prävalenz linksventrikulärer Hypertrophie bei unselektionierten Patienten einer allgemeininternistischen Ambulanz mit neu diagnostizierter Hypertonie. Abstract, Jahrestagung der Deutschen Liga zu Bekämpfung des hohen Blutdrucks, Heidelberg, 2000.
110. T. Dieterle, M. Weinbacher, E. Battegay, B. Martina. Losartan reduces left ventricular mass in patients with mild to moderate essential hypertension. Abstract, International Symposium on Angiotensin II receptor Antagonism, Monaco, 1999.
111. Gallacchi, S. Reichlin, P. Lindenlaub, B. Bucheli, T. Dieterle, R. Schoenenberger, B. Martina. Prädiktoren eines klinisch relevanten Systolikums bei Notfallstationspatienten. Schweiz Med Wochenschr 1999; 129, Suppl. 105/I: P51.
112. T. Dieterle, B. Martina, H. Schächinger, Ch. Haberthür, P. Gasser. Effects of acute ACE-inhibition and Angiotensin II on skin blood flow. Kidney Blood Press Res 1998; 21: 343.
113. T. Dieterle, B. Bucheli, V. Brenneisen, E. Battegay, B. Martina. Diagnostic value of oscillometric blood pressure monitors at the upper arm and the wrist. Eur J Clin Invest 1997; 27, Suppl. 1: 86.
114. Schächinger, B. Martina, T. Dieterle, C. Haberthür, P. Huber, A. Bock, R. Ritz, K. Gyr. Blunted renovascular response to subpressor angiotensin II after chronic ACE-inhibition in normotensives at risk for hypertension. Kidney International 1997; 52: 1423.
115. Schächinger, T. Dieterle, B. Martina, C. Haberthür, P. R. Huber, W. Langewitz, A. Bock, R. Ritz, K. Gyr. Renal factors in genetic predisposition to primary arterial hypertension. J Hypertens 1997; 15, Suppl. 4: 5B.3.
116. Schächinger, T. Dieterle, C. Haberthür, B. Martina, W. Langewitz, R. Ritz, K. Gyr. Spectral analysis of blood pressure variability and heart rate variability during ACE-Inhibition and Angiotensin II-infusion. Am J Hypertens 1996; 9, 4, Part 2: 124A.
117. B. Bucheli, T. Dieterle, V. Brenneisen, E. Battegay, B. Martina. Oszillometrische Blutdruckmessung: Oberarm vs. Handgelenk. Schweiz Med Wochenschr 1996; 126, Suppl. 74/I: P188.

118. R. Hambrecht, E. Fiehn, J. Niebauer, T. Dieterle, B. Offner, U. Riede, G. Schuler. Effects of physical exercise on oxidative enzyme activity and fiber type distribution in skeletal muscle of patients with chronic heart failure. *Circulation* 1995; 92, 8: Suppl. I, 1578.
119. Weirich, S. Hohnloser, T. Dieterle, H. Antoni. Inverse frequency-dependence of cardiac electrophysiological effects induced by d-Sotalol is consistent with a periodical interaction with closed potassium channels. *Pflüger's Arch* 1992; 420: Suppl. R85.
120. Weirich, S. Hohnloser, T. Dieterle, H. Antoni. Reverse use-dependence of d-Sotalol is consistent with slow on- and off-kinetics of a periodical interaction with potassium channels. *Naunyn-Schmiedeberg's Arch Pharmacol* 1992; 345: Suppl. R71.



Freiburg, 05.03.2025

Prof. Dr. med. Thomas Dieterle, MHBA